Imiquimod cream
Sponsors
Graceway Pharmaceuticals, LLC, University of Glasgow, The Royal Bournemouth Hospital, University of Utah, Toray Industries, Inc
Conditions
Actinic KeratosesActinic KeratosisBasal Cell CarcinomaBladder CancerCancerCholangiocarcinomaChronic Lymphocytic LeukemiaCirrhosis, Liver
Phase 1
Phase 2
Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients
TerminatedNCT00596336
Start: 2007-10-31End: 2017-03-15Updated: 2017-04-12
Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen
NCT05028322
Start: 2021-11-01End: 2024-12-01Target: 60Updated: 2021-08-31
Phase 3
Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
CompletedNCT00603798
Start: 2008-01-31End: 2008-07-31Updated: 2010-06-29
Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
CompletedNCT00605176
Start: 2008-01-31End: 2008-07-31Updated: 2010-06-29
Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery
CompletedNCT00894647
Start: 2009-05-31End: 2010-02-28Updated: 2010-08-31
Phase 4
Unknown Phase
A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base
NCT00463359
Target: 50Updated: 2007-04-20
Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna
CompletedNCT00707174
Start: 2005-03-31End: 2013-03-31Updated: 2013-07-31
Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children
NCT05315024
Start: 2022-04-30End: 2023-10-30Target: 72Updated: 2022-04-18